| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/01/2002 | WO2002058736A2 Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
| 08/01/2002 | WO2002058735A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | WO2002058734A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| 08/01/2002 | WO2002058733A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058732A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058731A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058712A2 Probiotic compounds derived from lactobacillus casei strain ke01 |
| 08/01/2002 | WO2002058711A1 Therapy-enhancing glucan |
| 08/01/2002 | WO2002058710A1 Tagatose as a novel treatment for metabolic syndrome x, dyslipidemia, and coronary artery disease |
| 08/01/2002 | WO2002058709A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | WO2002058708A1 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 08/01/2002 | WO2002058707A2 Method of treatment of type i diabetes with vitamin d compounds |
| 08/01/2002 | WO2002058706A2 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
| 08/01/2002 | WO2002058705A2 Degradation-resistant glucocorticosteroid formulations |
| 08/01/2002 | WO2002058704A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 08/01/2002 | WO2002058703A2 The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers |
| 08/01/2002 | WO2002058702A1 Urotensin-ii receptor antagonists |
| 08/01/2002 | WO2002058701A1 Pharmaceutical dosage forms of epothilones for oral administration |
| 08/01/2002 | WO2002058700A1 Methods of administering epothilone analogs for the treatment of cancer |
| 08/01/2002 | WO2002058699A1 Pharmaceutical forms of epothilones for oral administration |
| 08/01/2002 | WO2002058698A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | WO2002058697A1 Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| 08/01/2002 | WO2002058696A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | WO2002058695A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | WO2002058694A2 Method of treating hematologic tumors and cancers using beta lapachone |
| 08/01/2002 | WO2002058693A1 Metal salts of carnitines useful as dietary/nutritional supplements or drugs and compositions containing such salts |
| 08/01/2002 | WO2002058692A2 Halogenated composition, method for preparing same and uses thereof |
| 08/01/2002 | WO2002058691A1 Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds |
| 08/01/2002 | WO2002058690A2 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 08/01/2002 | WO2002058689A1 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same |
| 08/01/2002 | WO2002058688A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | WO2002058687A2 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics |
| 08/01/2002 | WO2002058686A2 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| 08/01/2002 | WO2002058685A2 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058684A2 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 08/01/2002 | WO2002058683A2 Carotenoids as anti-hypertension agents |
| 08/01/2002 | WO2002058682A2 An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation |
| 08/01/2002 | WO2002058681A2 Use of rhein for preparing a medicine for treating a high level of il-1 |
| 08/01/2002 | WO2002058680A2 Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| 08/01/2002 | WO2002058679A2 Antiangiogenic compounds and an assay for inhibitors of cell invasion |
| 08/01/2002 | WO2002058677A1 New film coating |
| 08/01/2002 | WO2002058676A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
| 08/01/2002 | WO2002058674A2 Process for preparing particles |
| 08/01/2002 | WO2002058673A1 Method of preparing pharmaceutical or dietary compositions for conveying labile substances into the intestine |
| 08/01/2002 | WO2002058672A2 Microparticles of biodegradable polymer encapsulating a biologically active substance |
| 08/01/2002 | WO2002058671A1 Burst free pharmaceutical microparticules |
| 08/01/2002 | WO2002058670A1 Local anesthetic, and method of use |
| 08/01/2002 | WO2002058669A1 Solid phase dispersion of quinolone- or naphthyridonecarboxylic acids |
| 08/01/2002 | WO2002058668A2 Artificial tear composition adapted to be used with contact lenses |
| 08/01/2002 | WO2002058666A2 Process for preparing non-hygroscopic sodium valproate composition |
| 08/01/2002 | WO2002058664A1 Use of an isothiocyanate, a thiocyanate or a mixture thereof as depigmenting agent |
| 08/01/2002 | WO2002058663A1 Method for the production and use of a cream containing vitamin-a. |
| 08/01/2002 | WO2002058640A1 Topical therapeutic skin care system |
| 08/01/2002 | WO2002058639A2 Pyranoflavonoid compounds and their use as estrogen receptor modulators |
| 08/01/2002 | WO2002058638A2 Serpin drugs for treatment of hiv infection and method of use thereof |
| 08/01/2002 | WO2002058636A2 Novel cannabimimetic ligands |
| 08/01/2002 | WO2002058634A2 ESTRADIOL-16α-CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058625A2 Herbal composition for angina pectoris, method to prepare same and uses thereof |
| 08/01/2002 | WO2002058623A2 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation |
| 08/01/2002 | WO2002058622A2 Sn-38 lipid complexes and methods of use |
| 08/01/2002 | WO2002058610A1 Alkyl aryl polyether alcohol polymers for improvement of nasal breathing |
| 08/01/2002 | WO2002058608A1 Loratadine transdermal device and methods |
| 08/01/2002 | WO2002058586A2 Systemic formulations containing beta-carotene and derivatives thereof |
| 08/01/2002 | WO2002058535A2 Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
| 08/01/2002 | WO2002058533A2 Process for determining target function and identifying drug leads |
| 08/01/2002 | WO2002058532A2 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof |
| 08/01/2002 | WO2002058483A1 Milk ingredient ameliorant and meat quality ameliorant for animal both containing acid derived from hexose |
| 08/01/2002 | WO2002058450A2 Regulation of cell growth by muc1 |
| 08/01/2002 | WO2002051424A8 Drugs against articular failure |
| 08/01/2002 | WO2002045749A3 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 08/01/2002 | WO2002043712A3 Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002041828A3 Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon |
| 08/01/2002 | WO2002036104A3 Inhalative solution formulation containing a tiotropium salt |
| 08/01/2002 | WO2002036066A3 Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia |
| 08/01/2002 | WO2002035987A3 METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES |
| 08/01/2002 | WO2002032410A3 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 08/01/2002 | WO2002032285A3 Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients |
| 08/01/2002 | WO2002032233A3 Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
| 08/01/2002 | WO2002030461A3 Methods for treating disorders of the female reproductive system |
| 08/01/2002 | WO2002030441A3 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 08/01/2002 | WO2002026733A3 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 08/01/2002 | WO2002024226A3 Photosensitisers |
| 08/01/2002 | WO2002022572A3 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 08/01/2002 | WO2002017963A3 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 08/01/2002 | WO2002016620A3 Modulation of stem cell differentiation |
| 08/01/2002 | WO2002014477A3 Bioavailable composition of natural and synthetic hca |
| 08/01/2002 | WO2002014319A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 08/01/2002 | WO2002012227A3 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 08/01/2002 | WO2002012190A3 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 08/01/2002 | WO2002011766A3 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 08/01/2002 | WO2002010152A3 Novel indole derivatives and their use as medicaments |
| 08/01/2002 | WO2002008190A3 Novel heteroaryl derivatives and use thereof as anti-tumour agents |
| 08/01/2002 | WO2002005794A3 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 08/01/2002 | WO2002002505A3 Compounds to treat alzheimer's disease |
| 08/01/2002 | WO2001098279A3 Bis-arylsulfones |